Slide
Securing
Connections
Corporate Profile
We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Press Releases
Events & Presentations
April 14, 2022 at 3:00 PM EDT
21st Annual Needham Virtual Healthcare Conference – April 11-14, 2022
Investor Presentation
March 24, 2022 at 4:30 PM EDT
Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call